## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.12 indicates fundamental undervaluation. Quality metrics strong (ROE 30%, ROA 14%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($88.67)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Incyte’s Blood Cancer Drug Shows Promise, But Hurdle Remain**
- Source: Finimize | 20251211T000848 | Neutral | Relevance: 100%
- Incyte released promising early trial results for its new blood cancer drug, INCA033989, targeting patients with specific genetic mutations. While the drug shows positive signs for safety and effectiveness and could be a rare disease-modifying option, RBC Capital Markets remains cautiously optimistic, noting the path forward involves challenges in dosing optimization and a complex phase 3 trial process. The firm also anticipates a smaller market than some investors expect, with Incyte's stock currently trading above RBC's price target, suggesting a largely priced-in valuation.

**2. Incyte Lures New Top Lawyer With Hefty Equity Package Tied to Performance**
- Source: MyChesCo | 20251213T170806 | Somewhat-Bullish | Relevance: 100%
- Incyte Corporation (INCY) has appointed Richard Hoffman as its new Executive Vice President and General Counsel, attracting him with a substantial equity-based compensation package. This package includes stock options, restricted stock units, and performance-based shares, designed to align Hoffman's long-term interests with the company's performance. The move highlights Incyte's strategy to secure top talent in a competitive market while emphasizing shareholder alignment.

**3. Bellevue Group AG Has $106.94 Million Holdings in Incyte Corporation $INCY**
- Source: MarketBeat | 20251213T110827 | Neutral | Relevance: 100%
- Bellevue Group AG recently reduced its stake in Incyte Corporation by 24.9% in the 2nd quarter, now holding 1,570,333 shares valued at approximately $106.94 million, representing 0.80% of Incyte's stock. Several other institutional investors have also adjusted their positions in Incyte, and company insiders have sold shares totaling over $2.7 million in the last quarter. Incyte's stock opened at $95.41 with a market cap of $18.73 billion, and analysts project $4.86 EPS for the current fiscal year, with an average "Hold" rating and a consensus target price of $99.07.

**4. Incyte director Hervé Hoppenot retires from board effective immediately**
- Source: Investing.com | 20251212T172822 | Neutral | Relevance: 100%
- Incyte Corporation announced the immediate retirement of Hervé Hoppenot from its board of directors. Hoppenot, who previously served as chairman and chief executive officer, had been a board member since 2014. The reason for his retirement was not disclosed in the SEC filing.

**5. Hervé Hoppenot resigns from Incyte’s board of directors**
- Source: Investing.com | 20251212T134415 | Somewhat-Bullish | Relevance: 100%
- Hervé Hoppenot has resigned from Incyte Corporation's Board of Directors, effective immediately, after serving as Chairman and CEO since 2014. Under his leadership, Incyte (NASDAQ:INCY) has achieved a strong financial position, with more cash than debt and a 38.8% stock price gain over the last six months. This transition follows a previously announced plan and coincides with recent positive clinical data for Incyte's experimental drug INCA033989, leading to increased price targets from several analyst firms.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |
| 2025-11-24 | Barclays | $115 | $101 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |
| 2025-11-24 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($0.15M) |
| Sells | 15 ($23.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Heavy insider selling: $23M sold (15 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.12 indicates undervaluation relative to growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($23.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.7B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 6.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.12 |
| Forward P/E | 12.4 |
| Current P/E | 14.0 |
| YoY Growth | 12.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -8.6% to -6.2% (+2.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 10.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.1%) - potential reversal signal. AM_20 at -5.8% indicates price below own 20MA trend. Underperforming sector by 5.9pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.24x) but short-term weakness (below SMA20). MACD histogram bearish (-1.40), momentum weakening. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -6.21% (CS: 4) | Weak |
| RSI_14 | 39.4 | Neutral |
| MACD Histogram | -1.40 | Bearish |
| vs SMA20 | 0.942x | Below |
| vs SMA50 | 0.988x | Below |
| vs SMA200 | 1.237x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $95.41
- **Stop Loss:** $88.67 (7.1% risk)
- **Target:** $108.89 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 148
- **Position Value:** $14,120.68
- **Portfolio %:** 14.12%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*